CA - HLS Therapeutics GAAP EPS of -$0.14 revenue of $15.7M
- HLS Therapeutics press release ( OTCPK:HLTRF ): Q3 GAAP EPS of -$0.14.
- Revenue of $15.7M (+4.0% Y/Y).
- Cash and cash equivalents was $21.3 million at September 30, 2022 compared to $21.2 million at December 31, 2021
For further details see:
HLS Therapeutics GAAP EPS of -$0.14, revenue of $15.7M